作者:Ambber Ward、Lilong Dong、Jonathan M. Harris、Kum Kum Khanna、Fares Al-Ejeh、David P. Fairlie、Adrian P. Wiegmans、Ligong Liu
DOI:10.1016/j.bmcl.2017.05.039
日期:2017.7
through small molecule inhibition of RAD51, thereby sensitizing tumor cells to DNA damaging irradiation and/or chemotherapy. Here we report structure-activity relationships for a library of quinazolinone derivatives. A novel RAD51 inhibitor (17) displays up to 15-fold enhanced inhibition of cell growth in a panel of TNBC cell lines compared to compound B02, and approximately 2-fold increased inhibition
RAD51是同源重组DNA修复途径的重要组成部分,在耐药性癌症(包括侵袭性三阴性乳腺癌(TNBC))中过表达。提出的改善患者治疗效果的策略是通过小分子抑制RAD51,从而使肿瘤细胞对DNA破坏性辐射和/或化学疗法敏感。在这里,我们报告喹唑啉酮衍生物库的结构活性关系。与化合物B02相比,新型RAD51抑制剂(17)在一组TNBC细胞系中对细胞生长的抑制作用提高了15倍,对辐射诱导的RAD51灶形成的抑制作用则提高了约2倍。此外,化合物17 显着抑制TNBC细胞对DNA损伤的敏感性,这意味着潜在的靶向疗法可用于癌症治疗。